Eupraxia Pharmaceuticals Inc. has seen notable fluctuations in its stock price this week, reflecting investor sentiment amidst recent company developments.
Eupraxia Pharmaceuticals Inc. (EPRX.TO) faced a challenging week, with its stock price declining by 7.91% over the past five days. As of the latest trading session, the stock closed at C$9.10, down 1.99% for the day. This movement comes against a backdrop of recent public offerings and financial reporting that have influenced market perception.
Investor takeaway: Investors should consider the implications of Eupraxia's recent public offerings and financial performance when evaluating the stock's potential. The company's focus on developing innovative therapies may offer long-term growth opportunities, but the current volatility suggests caution in the short term.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$558.55M
52W high
$12.86
52W low
$6.94
1W change
-7.91%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 94.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+94.9% Upside
Current Price
C$8.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
55.7%
Annualized
90-Day Vol
57.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$7.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$7.90 | C$6.51 – C$9.57 |
| 60 trading days | C$7.44 | C$5.67 – C$9.76 |
| 90 trading days | C$7.01 | C$5.02 – C$9.78 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Eupraxia's Stock Declines 7.91% This Week Amidst Market Volatility.
With a market cap of approximately C$558.5 million and a beta of 1.50, Eupraxia's stock shows higher volatility compared to the broader market, indicating potential risks for investors.
Bull case
The recent public offering raised about US$63.2 million, which could enhance Eupraxia's financial stability and support ongoing clinical trials for its lead product, EP-104GI. Analysts remain optimistic, with an average price target of C$16.33, suggesting significant upside potential from current levels.
Bear case
However, the stock's recent performance, including a year-to-date decline of nearly 20%, raises concerns about market confidence in Eupraxia's growth trajectory. The company's negative profit margin and return on equity may deter risk-averse investors.
Recent Price Action
Advertisement
Eupraxia Pharmaceuticals Inc. (EPRX.TO) has seen a downward trend this week, with its stock price closing at C$9.10, reflecting a 1.99% decline on the day and a 7.91% drop over the past week. This decline is part of a broader trend, as the stock has decreased by 10.37% in the past month and nearly 20% year-to-date.
Company News and Developments
Despite the recent downturn in stock price, Eupraxia has been active in the capital markets. The company recently completed a public offering, raising approximately US$63.2 million to support its clinical programs. This financing could provide the necessary funds for further development of its lead product, EP-104GI, which aims to address significant medical needs.
Technical Picture
From a technical standpoint, Eupraxia's stock is currently trading just below its 50-day moving average of C$9.13 and significantly below its 200-day moving average of C$9.73. The stock's 52-week range has been between C$6.94 and C$12.86, indicating it is currently near the lower end of this range. The recent trading volume of 79,179 shares represents a 1.15x increase compared to the 20-day average volume of 63,216 shares, suggesting increased trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
